Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. The work includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments as part of Onco-Innovations’ chemistry, manufacturing and controls strategy.
The company said the activities are intended to establish a scalable, reproducible and analytically characterized polymer platform to support future formulation, manufacturing, regulatory and clinical development. Onco-Innovations said Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform while supporting future GMP manufacturing readiness.
This development is significant because it moves ONC010 closer to clinical trials. By partnering with Nanosoft, Onco-Innovations is addressing a critical bottleneck in nanomedicine: the transition from laboratory-scale synthesis to reproducible, large-scale production. The focus on analytical characterization ensures that the polymer platform can be consistently manufactured to meet regulatory standards, a key requirement for Investigational New Drug (IND) applications.
ONC010 targets Polynucleotide Kinase Phosphatase (PNKP), an enzyme involved in DNA repair that is often overexpressed in cancer cells. By inhibiting PNKP, the drug aims to sensitize tumors to radiation and chemotherapy. The nanoparticle formulation is designed to improve drug delivery and reduce systemic toxicity.
For Onco-Innovations, this collaboration de-risks the manufacturing process and builds confidence for future investors and partners. The company has secured an exclusive worldwide license to patented technology targeting solid tumors, and the progress on ONC010 could validate its platform.
Investors can find the latest news and updates relating to ONNVF in the company’s newsroom at https://nnw.fm/ONNVF. The full press release is available at https://nnw.fm/BeSoS.
